title: Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.
abstract: The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators and cytotoxic agents extensively used in the treatment of autoimmune diseases, graft rejection, and cancer. There is compelling epidemiologic evidence that thiopurine treatment increases the risk for a variety of tumors by mechanisms that are unclear. We investigated the in vivo mutagenicity of long-term thiopurine treatment by determining the frequency and spectra of somatic mutation events at the hypoxanthine phosphoribosyltransferase (HPRT) locus in peripheral T lymphocytes as well as the prevalence of mutant clonal proliferation in a cross-sectional analysis of data from 119 children and adults with inflammatory bowel disease (IBD). ANOVA and regression were performed to assess relationships among the frequency and spectra of HPRT mutations with disease, duration of illness, duration of treatment, and total therapeutic dose of azathioprine and 6-MP. We observed a significant increase in the frequency of somatic mutations in 56 subjects treated with thiopurines for IBD compared with 63 subjects not treated with thiopurines. This increase was related to both total dose (P < 0.001) and duration of treatment (P < 0.001). Comparative mutation spectra analysis of 1,020 mutant isolates revealed a significant increase in the proportion of all transitions (P < 0.001), particularly G:C to A:T transitions (P < 0.001). Combined analyses of two signatures for mutant clonality, HPRT mutation, and T-cell receptor beta CDR3 region unique gene sequence also showed a significant thiopurine-dependent increase in mutant cell clonal proliferation (P < 0.001). These findings provide in vivo evidence for mutation induction as a potential carcinogenic mechanism associated with chronic thiopurine intervention.
authors.affiliation: Department of Pediatrics, University of Vermont, Burlington, Vermont 05445-0068, USA.
authors.forename: Truc
authors.initials: T
authors.lastname: Nguyen
authors.forename: Pamela M
authors.initials: PM
authors.lastname: Vacek
authors.forename: Patrick
authors.initials: P
authors.lastname: O'Neill
authors.forename: Richard B
authors.initials: RB
authors.lastname: Colletti
authors.forename: Barry A
authors.initials: BA
authors.lastname: Finette
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D002273:Carcinogens / Q000633:toxicity; D049109:Cell Proliferation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects* / Q000627:therapeutic use; D009152:Mutagenicity Tests; D009153:Mutagens / Q000009:adverse effects; D009154:Mutation / Q000187:drug effects*; D012044:Regression Analysis; D013601:T-Lymphocytes / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology
chemical_list: D002273:Carcinogens; D007166:Immunosuppressive Agents; D009153:Mutagens; D015122:Mercaptopurine; D007041:Hypoxanthine Phosphoribosyltransferase; D001379:Azathioprine
references.citation: Cancer Res. 1971 Nov;31(11):1627-31
references.pmid: 5287342
references.citation: Am J Transplant. 2004 Jun;4(6):905-13
references.pmid: 15147424
references.citation: Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17
references.pmid: 15194558
references.citation: Science. 2005 Sep 16;309(5742):1871-4
references.pmid: 16166520
references.citation: Leukemia. 2001 Dec;15(12):1898-905
references.pmid: 11753611
references.citation: Circulation. 1995 Aug 15;92(4):862-74
references.pmid: 7641367
references.citation: Ann Rheum Dis. 1988 Dec;47(12):988-92
references.pmid: 3207388
references.citation: Expert Opin Investig Drugs. 2005 Mar;14(3):295-304
references.pmid: 15833060
references.citation: Annu Rev Genet. 1990;24:305-26
references.pmid: 2088171
references.citation: Mutat Res. 2002 Aug 29;505(1-2):27-41
references.pmid: 12175903
references.citation: Inflamm Bowel Dis. 2008 Oct;14(10):1425-31
references.pmid: 18383175
references.citation: Mutat Res. 2001 Oct;489(1):1-16
references.pmid: 11673087
references.citation: Clin Transplant. 2005 Apr;19(2):279-85
references.pmid: 15740568
references.citation: Inflamm Bowel Dis. 2007 Aug;13(8):1024-30
references.pmid: 17480018
references.citation: Blood. 2005 May 15;105(10):3802-11
references.pmid: 15687239
references.citation: Lancet Oncol. 2009 Jan;10(1):13-4
references.pmid: 19115512
references.citation: Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):586-91
references.pmid: 9892677
references.citation: Dig Dis Sci. 2004 Jan;49(1):133-7
references.pmid: 14992447
references.citation: Scand J Immunol. 2000 Jun;51(6):626-33
references.pmid: 10849375
references.citation: Genomics. 1990 Jun;7(2):235-44
references.pmid: 2347587
references.citation: Biochem Pharmacol. 1997 Aug 1;54(3):419-24
references.pmid: 9278101
references.citation: Cancer Res. 1996 Mar 15;56(6):1405-12
references.pmid: 8640832
references.citation: Science. 1996 Aug 23;273(5278):1109-11
references.pmid: 8688098
references.citation: Blood. 2004 Aug 1;104(3):822-8
references.pmid: 15090454
references.citation: Blood. 1996 Jan 1;87(1):386-92
references.pmid: 8547667
references.citation: Science. 2000 Apr 21;288(5465):514-7
references.pmid: 10775110
references.citation: Bone Marrow Transplant. 2001 Jul;28(2):121-9
references.pmid: 11509929
references.citation: J Biol Chem. 2008 Aug 29;283(35):23665-70
references.pmid: 18591241
references.citation: J Rheumatol. 1999 Aug;26(8):1705-14
references.pmid: 10451066
references.citation: Arthritis Rheum. 1994 Feb;37(2):270-7
references.pmid: 8129782
references.citation: Mutat Res. 1994 Jul 16;308(2):223-31
references.pmid: 7518049
references.citation: Lancet. 1999 Jul 3;354(9172):34-9
references.pmid: 10406363
references.citation: Environ Mol Mutagen. 1999;34(2-3):131-9
references.pmid: 10529737
references.citation: Nat Med. 1998 Oct;4(10):1144-51
references.pmid: 9771747
references.citation: Cancer Res. 1974 Apr;34(4):738-46
references.pmid: 4856046
references.citation: Br Med Bull. 2006;79-80:153-70
references.pmid: 17277075
references.citation: Clin Immunol. 1999 Apr;91(1):61-7
references.pmid: 10219255
references.citation: Mutat Res. 1993 Feb;285(2):267-79
references.pmid: 7678900
references.citation: Science. 1989 Apr 7;244(4900):41-7
references.pmid: 2649979
references.citation: Gut. 2005 Aug;54(8):1121-5
references.pmid: 16009685
references.citation: Mutat Res. 1997 Jun 9;377(1):115-23
references.pmid: 9219586
references.citation: Clin Pharmacokinet. 2007;46(3):187-208
references.pmid: 17328579
references.citation: Cancer Res. 2006 Sep 1;66(17):8455-61
references.pmid: 16951156
references.citation: Oncogene. 2002 Oct 10;21(46):7126-30
references.pmid: 12370835
references.citation: Nat Rev Cancer. 2008 Jan;8(1):24-36
references.pmid: 18097462
references.citation: Genetics. 1999 Jul;152(3):1065-77
references.pmid: 10388825
references.citation: Liver. 1987 Apr;7(2):81-3
references.pmid: 3613879
references.citation: Pediatr Transplant. 1998 Feb;2(1):56-63
references.pmid: 10084762
references.citation: Mutat Res. 2000 Jun 22;468(1):45-61
references.pmid: 10863157